$160,000 of CLARITEV (FORMERLY MULTIPLAN CORPORATION) lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to healthcare reimbursement; issues related to payment and revenue integrity; and issues related to price and coverage transparency Issues related to healthcare reimbursement; issues related to payment and revenue integrity; and issues related to price and coverage transparency"
You can find more data on corporate lobbying on Quiver Quantitative.
CTEV Insider Trading Activity
CTEV insiders have traded $CTEV stock on the open market 10 times in the past 6 months. Of those trades, 10 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CTEV stock by insiders over the last 6 months:
- DOUGLAS MICHAEL GARIS (EVP&CFO) has made 6 purchases buying 41,268 shares for an estimated $907,953 and 0 sales.
- JEROME HOGGE (EVP, Chief Operating Officer) purchased 12,500 shares for an estimated $349,250
- TRAVIS DALTON (Pres., CEO & Executive Chair) has made 2 purchases buying 9,025 shares for an estimated $200,807 and 0 sales.
- TARA O'NEIL (SVP, General Counsel) purchased 440 shares for an estimated $9,605
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CTEV Analyst Ratings
Wall Street analysts have issued reports on $CTEV in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 05/29/2025
To track analyst ratings and price targets for CTEV, check out Quiver Quantitative's $CTEV forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
